amsacrine has been researched along with Thrombopenia in 15 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amsacrine was administered to 73 evaluable patients with previously treated malignant lymphoma in the Southwest Oncology Group." | 7.66 | Phase II study of amsacrine (m-AMSA) in advanced lymphomas: a Southwest Oncology Group study. ( Jones, SE; Ryan, DH; Weick, JK, 1983) |
| "Amsacrine was administered to 73 evaluable patients with previously treated malignant lymphoma in the Southwest Oncology Group." | 3.66 | Phase II study of amsacrine (m-AMSA) in advanced lymphomas: a Southwest Oncology Group study. ( Jones, SE; Ryan, DH; Weick, JK, 1983) |
| "Thus, the CR rate for relapsed ANLL patients who received the higher doses of both agents was 40% (13 of 33)." | 1.28 | Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine. ( Dahl, GV; Grier, HE; Kalwinsky, DK; Mason, C; Mirro, J; Murphy, SB; Santana, VM, 1989) |
| "Leukopenia was the dose-limiting toxicity with 7." | 1.27 | The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II study. ( Amrein, PC; Carey, RW; Coleman, M; Green, MR; Holland, JF; Kennedy, BJ; Poulin, RF; Richards, F; Weil, M; Weinberg, V, 1984) |
| "Patients with acute leukemia in relapse were given 5'-(9-acridinylamino)methanesulfon-m-anisidide at a dosage of 75 to 200 mg/sq m as a daily bolus infusion of 5 consecutive days." | 1.26 | Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia. ( Arlin, ZA; Clarkson, BD; Gee, TS; Howard, J; Kempin, SJ; Sklaroff, RB; Young, CW, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (93.33) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bukowski, RM | 1 |
| Leichman, LP | 1 |
| Rivkin, SE | 1 |
| Falkson, G | 1 |
| MacIntyre, JM | 1 |
| Schutt, AJ | 1 |
| Coetzer, B | 1 |
| Johnson, LA | 1 |
| Simson, IW | 1 |
| Douglass, HO | 1 |
| Amrein, PC | 2 |
| Poulin, RF | 2 |
| Coleman, M | 2 |
| Richards, F | 2 |
| Weil, M | 1 |
| Kennedy, BJ | 2 |
| Carey, RW | 1 |
| Green, MR | 1 |
| Holland, JF | 1 |
| Weinberg, V | 1 |
| Bramwell, VH | 1 |
| Holdener, EE | 1 |
| Siegenthaler, P | 1 |
| Ten Bokkel Huinink, W | 1 |
| Bruntsch, U | 1 |
| Renard, J | 1 |
| van Glabbeke, M | 1 |
| Weick, JK | 1 |
| Jones, SE | 1 |
| Ryan, DH | 1 |
| Berkowitz, I | 1 |
| Green, M | 1 |
| Herschkopf, R | 1 |
| Rafla, S | 1 |
| Schneider, RJ | 2 |
| Woodcock, TM | 2 |
| Yagoda, A | 1 |
| Young, CW | 2 |
| Buzdar, AU | 1 |
| Legha, SS | 1 |
| Hortobagyi, GN | 1 |
| Powell, KC | 1 |
| Blumenschein, GR | 1 |
| Bodey, GP | 1 |
| Arlin, ZA | 1 |
| Sklaroff, RB | 1 |
| Gee, TS | 1 |
| Kempin, SJ | 1 |
| Howard, J | 1 |
| Clarkson, BD | 1 |
| Navarro, JT | 1 |
| Hernández, JA | 1 |
| Ribera, JM | 1 |
| Sancho, JM | 1 |
| Oriol, A | 1 |
| Pujol, M | 1 |
| Millá, F | 1 |
| Feliu, E | 1 |
| Mukaiyama, T | 1 |
| Ogawa, M | 1 |
| Horikoshi, N | 1 |
| Inoue, K | 1 |
| Fukutani, H | 1 |
| Tabata, M | 1 |
| Hirano, A | 1 |
| Mizunuma, N | 1 |
| Itami, S | 1 |
| Mirro, J | 1 |
| Kalwinsky, DK | 1 |
| Grier, HE | 1 |
| Santana, VM | 1 |
| Mason, C | 1 |
| Murphy, SB | 1 |
| Dahl, GV | 1 |
| Dhaliwal, HS | 1 |
| Shannon, MS | 1 |
| Barnett, MJ | 1 |
| Prentice, HG | 1 |
| Bragman, K | 1 |
| Malpas, JS | 1 |
| Lister, TA | 1 |
| Civin, CI | 1 |
| Krischer, JP | 1 |
| Land, VJ | 1 |
| Nitschke, R | 1 |
| Kamen, B | 1 |
| Vats, T | 1 |
1 trial available for amsacrine and Thrombopenia
| Article | Year |
|---|---|
Neocarzinostatin versus m-AMSA or doxorubicin in hepatocellular carcinoma.
Topics: Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Clinical Trials a | 1984 |
14 other studies available for amsacrine and Thrombopenia
| Article | Year |
|---|---|
Phase II trial of m-AMSA in gallbladder and cholangiocarcinoma: a Southwest Oncology Group Study.
Topics: Adenoma, Bile Duct; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Bile Duct Neoplas | 1983 |
The treatment of melanoma with m-AMSA. A Cancer and Leukemia Group B phase II study.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leuk | 1984 |
Phase II study of amsacrine in refractory lymphomas. A report of the EORTC Early Clinical Trials Group.
Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Evaluation; Female; | 1984 |
Phase II study of amsacrine (m-AMSA) in advanced lymphomas: a Southwest Oncology Group study.
Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Evaluation; Hodgkin | 1983 |
Phase II study of amsacrine in metastatic renal cell carcinoma: a Cancer and Leukemia Group B study.
Topics: Adenocarcinoma; Adult; Aged; Aminoacridines; Amsacrine; Bone Marrow; Drug Evaluation; Female; Humans | 1983 |
Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma.
Topics: Adenocarcinoma; Adult; Aged; Aminoacridines; Amsacrine; Drug Evaluation; Female; Humans; Kidney Neop | 1980 |
Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Dose-Response Relationship, Drug; Dru | 1980 |
AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Dr | 1982 |
Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Drug Administration Schedule; Drug Evaluation; Humans; | 1980 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; C | 1998 |
[4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun | 1989 |
Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; C | 1989 |
Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside.
Topics: Aged; Amsacrine; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Gastrointestinal Diseas | 1986 |
Pediatric oncology group phase II trial of amsacrine in children with solid tumors.
Topics: Age Factors; Aminoacridines; Amsacrine; Arrhythmias, Cardiac; Child; Child, Preschool; Drug Evaluati | 1985 |